Town & Country Bank & Trust CO dba First Bankers Trust CO Increases Holdings in Johnson & Johnson (NYSE:JNJ)

Share on StockTwits

Town & Country Bank & Trust CO dba First Bankers Trust CO lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 3.4% in the 3rd quarter, Holdings Channel reports. The firm owned 36,041 shares of the company’s stock after acquiring an additional 1,192 shares during the period. Johnson & Johnson accounts for 2.1% of Town & Country Bank & Trust CO dba First Bankers Trust CO’s portfolio, making the stock its 12th biggest holding. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Johnson & Johnson were worth $4,663,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of JNJ. Signet Financial Management LLC grew its holdings in Johnson & Johnson by 3.4% during the 4th quarter. Signet Financial Management LLC now owns 25,553 shares of the company’s stock worth $3,298,000 after acquiring an additional 848 shares during the last quarter. Semmax Financial Advisors Inc. bought a new stake in Johnson & Johnson during the 4th quarter worth about $421,000. Cohen & Steers Inc. grew its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Cohen & Steers Inc. now owns 209,577 shares of the company’s stock worth $27,046,000 after acquiring an additional 25,551 shares during the last quarter. Polar Capital LLP grew its holdings in Johnson & Johnson by 17.1% during the 4th quarter. Polar Capital LLP now owns 1,463,500 shares of the company’s stock worth $188,865,000 after acquiring an additional 213,500 shares during the last quarter. Finally, Drexel Morgan & Co. grew its holdings in Johnson & Johnson by 1.9% during the 4th quarter. Drexel Morgan & Co. now owns 19,696 shares of the company’s stock worth $2,542,000 after acquiring an additional 369 shares during the last quarter. Hedge funds and other institutional investors own 72.01% of the company’s stock.

A number of research firms have issued reports on JNJ. Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, August 27th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Barclays began coverage on shares of Johnson & Johnson in a research report on Friday, June 21st. They set a “hold” rating and a $140.00 target price on the stock. Bank of America restated a “hold” rating and set a $150.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Finally, Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price on the stock. in a research report on Thursday, July 18th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Johnson & Johnson has an average rating of “Buy” and an average price target of $151.00.

Johnson & Johnson stock traded up $3.53 during trading hours on Friday, reaching $132.59. 2,519,223 shares of the company’s stock traded hands, compared to its average volume of 6,702,304. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The firm has a market capitalization of $347.95 billion, a price-to-earnings ratio of 16.21, a PEG ratio of 2.22 and a beta of 0.69. The firm’s 50 day moving average is $129.92 and its 200-day moving average is $135.00.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.42 by $0.16. The company had revenue of $20.56 billion for the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The company’s revenue was down 1.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.10 EPS. Analysts predict that Johnson & Johnson will post 8.59 EPS for the current year.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Market Timing – The Benefits and the Danger

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.